GlycoBioSciences v. Dermalogica: Voluntary Dismissal in Hyaluronic Acid Patent Case

In a patent dispute that lasted just 56 days, GlycoBioSciences, Inc. voluntarily dismissed its infringement action against skincare brand Dermalogica, LLC before the defendant had even filed an answer. Filed on September 9, 2025, in the U.S. District Court for the Eastern District of Texas and closed November 4, 2025, Case No. 4:25-cv-00991 targeted several of Dermalogica’s premium hyaluronic acid-based skincare products, alleging infringement of two issued U.S. patents covering glycobiology-related formulations.

While the case produced no merits ruling, its rapid resolution through Rule 41(a)(1)(A)(i) voluntary dismissal without prejudice carries significant strategic weight. For patent practitioners, IP managers, and R&D teams in the cosmetics and personal care sector, this outcome illustrates critical dynamics in pre-answer patent assertion strategy, venue selection in the Eastern District of Texas, and the commercial leverage dynamics that shape early-stage patent litigation decisions.

Case Overview

The Parties

The Patents at Issue

Two U.S. patents were asserted in this action:

• • U.S. Patent No. 9,821,005 B2 — Covers formulations or methods relating to glycobiological or hyaluronic acid-based therapeutic or cosmetic compositions.
• • U.S. Patent No. 10,332,142 B2 — A related patent in the same technology family, directed to similar hyaluronic acid or glycan-based skincare chemistry or delivery innovations.

Both patents sit within the hyaluronic acid skincare patent landscape — a rapidly expanding and commercially contested IP space driven by surging consumer demand for hydration-focused cosmeceuticals.

The Accused Products

GlycoBioSciences targeted five specific Dermalogica products:

• • Circular Hydration Serum with Hyaluronic Acid
• • Hyaluronic Ceramide Mist
• • Phyto Nature Lifting Eye Cream
• • Phyto Nature Firming Serum
• • Phyto Nature Oxygen Cream

These represent core SKUs in Dermalogica’s premium hydration and anti-aging lines — high-revenue products where a successful injunction or royalty judgment would carry substantial commercial consequence.

Litigation Timeline & Procedural History

The complaint was filed in the U.S. District Court for the Eastern District of Texas, presided over by Chief Judge Amos L. Mazzant — a venue long favored by patent plaintiffs for its historically efficient case management and plaintiff-friendly procedural reputation, though post-TC Heartland dynamics continue to shape venue strategy in this district.

The case closed at the first-instance district court level, never reaching claim construction, summary judgment, or trial. No answer or responsive motion was filed by Dermalogica prior to the plaintiff’s voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), which permits dismissal as of right before service of an answer or motion for summary judgment.

The 56-day lifespan is notably short even for early-resolved patent cases, suggesting that whatever strategic or commercial calculation prompted the filing, it changed — or was resolved — rapidly after suit was initiated.

Legal Representation

Plaintiff GlycoBioSciences was represented by Benjamin Charles Deming and Joseph Jude Zito of **DNL Zito**, a boutique IP litigation firm. No defendant counsel was entered of record prior to dismissal, consistent with the pre-answer timing of the voluntary dismissal.

The Verdict & Legal Analysis

Outcome

GlycoBioSciences voluntarily dismissed the action without prejudice pursuant to Rule 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. Because the dismissal was without prejudice and entered before Dermalogica answered, GlycoBioSciences retains the right to refile the same claims — against the same defendant, on the same patents — in the future.

Critically, this is not a defendant win on the merits. Dermalogica obtained no invalidity ruling, no non-infringement finding, and no fee award. The slate is legally clean for both parties.

Verdict Cause Analysis

The case was initiated as a patent infringement action. No claim construction order, Markman hearing, or substantive ruling was issued before dismissal. The absence of any defendant filings means the court never evaluated:

• • Whether the asserted claims of US9821005B2 or US10332142B2 were valid
• • Whether the five accused Dermalogica products practiced any claim element
• • Whether literal infringement or the doctrine of equivalents applied
• • Any affirmative defenses (invalidity, non-infringement, prosecution history estoppel)

The legal record is procedurally thin by design — Rule 41(a)(1)(A)(i) dismissals are among the cleanest exits available in federal litigation.

Legal Significance

Why does a voluntary pre-answer dismissal matter analytically?

Pre-answer voluntary dismissals in patent cases often signal one of several strategic realities: a licensing negotiation that succeeded (or failed irreparably), a plaintiff reassessment of claim strength after filing, a challenge to venue or jurisdiction communicated informally, or a business resolution reached outside formal proceedings. Without disclosed settlement terms, the exact catalyst here is not determinable from the record.

What is legally significant is the without prejudice designation. Under Rule 41(a), a second voluntary dismissal of the same claim against the same party would operate as an adjudication on the merits — the so-called “two-dismissal rule.” Patent counsel representing GlycoBioSciences should be mindful of this limitation if reassertion is contemplated.

The Eastern District of Texas venue selection — before a defendant answer was even filed — remains a tactical data point. Plaintiffs continue to evaluate this district’s procedural posture even post-TC Heartland, particularly for defendants with sufficient jurisdictional contacts.

Strategic Takeaways

For Patent Holders:

Early-stage dismissals without prejudice preserve optionality but consume filing resources and may telegraph claim weakness to sophisticated defendants. Ensure pre-filing claim charts are rigorously mapped to accused product formulations before initiating suit in high-scrutiny venues.

For Accused Infringers:

A without-prejudice dismissal is not a safe harbor. Companies in the hyaluronic acid and glycobiological skincare space should use this window to conduct thorough freedom-to-operate (FTO) analyses against US9821005B2 and US10332142B2, evaluate inter partes review (IPR) petition viability at the USPTO’s Patent Trial and Appeal Board (PTAB), and document design-around considerations before any refiling occurs.

For R&D Teams:

The five accused products represent formulation categories — hydration serums, ceramide mists, lifting creams — that are commonplace across premium skincare. Any R&D team developing hyaluronic acid delivery systems should audit their formulations against the claim scope of both asserted patents.

Industry & Competitive Implications

The hyaluronic acid skincare patent landscape has grown increasingly contested as the global hyaluronic acid market — valued in the multi-billion dollar range — attracts both established cosmetic brands and specialty biotechnology patent holders. GlycoBioSciences’ assertion against five commercially prominent Dermalogica SKUs reflects a broader trend of glycobiology IP being leveraged against mainstream personal care product lines.

For companies operating in the cosmeceutical, dermatological skincare, and active ingredient formulation space, this case signals that hyaluronic acid delivery patents — particularly those covering ceramide co-formulations and multi-active serums — are being actively asserted. Patent portfolios in this space warrant ongoing monitoring.

The rapid resolution also reflects an emerging pattern: short-duration patent assertions in specialty chemical and cosmeceutical sectors often function as licensing conversations conducted under litigation pressure, rather than full-scale merits disputes. IP counsel advising beauty and personal care brands should build pre-litigation response frameworks that enable fast, informed decision-making when complaints are served.

*Explore related patent activity via the USPTO Patent Full-Text Database and the PACER federal court filing system for updated docket monitoring.*

📩 Subscribe to our patent litigation intelligence briefing for ongoing coverage of hyaluronic acid and cosmeceutical IP disputes.

🔍 Explore related cases in glycobiology and personal care patent litigation.

💼 Contact our IP team for a freedom-to-operate analysis or case strategy consultation.

❓ Frequently Asked Questions